<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d87ff31d-3d0c-4f33-bdf2-7d19191078a8"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS.
 <br/>
      <br/>
POTASSIUM CHLORIDE extended-release tablets, for oral use
 <br/>
Initial U.S. Approval: 1948</title>
   <effectiveTime value="20250227"/>
   <setId root="bf632e1d-73f3-4df1-ad12-e555fa6a56e9"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="050052943" root="1.3.6.1.4.1.519.1"/>
            <name>NCS HealthCare of KY, LLC dba Vangard Labs</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="050052943" root="1.3.6.1.4.1.519.1"/>
                        <name>NCS HealthCare of KY, LLC dba Vangard Labs</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0615-8570" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="251b4d71-8cab-4a66-8a19-4cde41202db9"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250227"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0615-8570" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Potassium Chloride</name>
                        <formCode code="C42930" displayName="TABLET, FILM COATED, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Potassium Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="42806-423" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="750"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z82Y2C65EA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROGENATED COTTONSEED OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1DI56QDM62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LECITHIN, SOYBEAN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0615-8570-39" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250224"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="15"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0615-8570-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250224"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="14"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0615-8570-14" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250224"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209314" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230807"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">YH;105;10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_1e51c689-720a-48d6-8451-41c1f4f5f511">
               <id root="1e51c689-720a-48d6-8451-41c1f4f5f511"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Potassium Chloride Extended-Release Tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.</paragraph>
               </text>
               <effectiveTime value="20240315"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Potassium Chloride Extended-Release Tablets are a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
 
    (1)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_758eeda7-fd4f-4f6a-b2a3-46635720335e">
               <id root="758eeda7-fd4f-4f6a-b2a3-46635720335e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20180510"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Monitor serum potassium and adjust dosages accordingly
  
     (2.1)</item>
                           <item>If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation
  
     (2.1)</item>
                           <item>Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking.
  
     (2.1)</item>
                           <item>
                              <content styleCode="underline">Treatment of hypokalemia</content>: Doses range from 40 to100 mEq/day in divided doses. Limit doses to 40 mEq per dose.
  
     <linkHtml href="#LINK_b2ca6f73-78c0-4274-9d16-1b8e5eeebe68">(2.2)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Prevention of</content>
                              <content styleCode="underline">hypokalemia</content>: Typical dose is 20 mEq per day.
  
     <linkHtml href="#LINK_b2ca6f73-78c0-4274-9d16-1b8e5eeebe68">(2.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_7879894b-ac73-472a-9cdf-538889f8e1f7">
                     <id root="7879894b-ac73-472a-9cdf-538889f8e1f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Administration and Monitoring</title>
                     <text>
                        <paragraph>If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Monitoring</content>
                        </paragraph>
                        <paragraph>Monitor serum potassium and adjust dosages accordingly. Monitor serum potassium periodically during maintenance therapy to ensure potassium remains in desired range.</paragraph>
                        <paragraph>The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms, and the clinical status of the patient. Correct volume status, acid-base balance, and electrolyte deficits as appropriate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Administration</content>
                        </paragraph>
                        <paragraph>Take potassium chloride extended-release tablets with meals and with a glass of water or other liquid. Do not take potassium chloride extended-release tablets on an empty stomach because of its potential for gastric irritation
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#LINK_bc19f3ec-9029-4c8b-be8c-cbb0a3bff0ad">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>Swallow tablets whole without crushing, chewing or sucking.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b2ca6f73-78c0-4274-9d16-1b8e5eeebe68">
                     <id root="b2ca6f73-78c0-4274-9d16-1b8e5eeebe68"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosing</title>
                     <text>
                        <paragraph>Dosage must be adjusted to the individual needs of each patient. Dosages greater than 40 mEq per day should be divided such that no more than 40 mEq is given in a single dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Treatment of Hypokalemia:</content>Typical dose range is 40 to 100 mEq per day.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Maintenance or Prophylaxis:</content>Typical dose range is 20 mEq per day.

 </paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c49c3513-2f8e-476e-8b69-19be56c42edf">
               <id root="c49c3513-2f8e-476e-8b69-19be56c42edf"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Potassium Chloride Extended-Release Tablets,USP are supplied as:</paragraph>
                  <paragraph>The 8 mEq (600 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “106” on one side, and “8” on the other side.</paragraph>
                  <paragraph>The 10 mEq (750 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “105” on one side, and “10” on the other side.</paragraph>
               </text>
               <effectiveTime value="20180827"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 600 mg (8 mEq) and 750 mg (10 mEq)
 
    (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_cbe886dc-ed0c-4b71-a30b-e3c85a2b00f3">
               <id root="cbe886dc-ed0c-4b71-a30b-e3c85a2b00f3"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Potassium chloride is contraindicated in patients on triamterene and amiloride.</paragraph>
               </text>
               <effectiveTime value="20180510"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Concomitant use with triamterene and amiloride
  
     (4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_5c15b919-eff7-4faf-939d-c96ec10afb63">
               <id root="5c15b919-eff7-4faf-939d-c96ec10afb63"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20180510"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Gastrointestinal Irritation: Take with meals
  
     <linkHtml href="#LINK_bc19f3ec-9029-4c8b-be8c-cbb0a3bff0ad">(5.1)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_bc19f3ec-9029-4c8b-be8c-cbb0a3bff0ad">
                     <id root="bc19f3ec-9029-4c8b-be8c-cbb0a3bff0ad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Gastrointestinal Adverse Reactions</title>
                     <text>
                        <paragraph>Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly if the drug maintains contact with the gastrointestinal mucosa for prolonged periods. Consider the use of liquid potassium in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders.</paragraph>
                        <paragraph>If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue potassium chloride extended-release tablets and consider possibility of ulceration, obstruction or perforation.</paragraph>
                        <paragraph>Potassium chloride extended-release tablets should not be taken on an empty stomach because of its potential for gastric irritation
 
  <content styleCode="italics">[see Dosage and Administration
  
   <linkHtml href="#LINK_7879894b-ac73-472a-9cdf-538889f8e1f7">(2.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5901ee00-4470-42f1-89ea-2bfa629ad693">
               <id root="5901ee00-4470-42f1-89ea-2bfa629ad693"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text/>
               <effectiveTime value="20230315"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>The most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea.
  
     (6)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC at 1-888-374-2791 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a4619ace-84e4-4648-876e-5a854e9e1426">
                     <id root="a4619ace-84e4-4648-876e-5a854e9e1426"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.</paragraph>
                        <paragraph>There have been reports hyperkalemia and of upper and lower gastrointestinal condition including obstruction, bleeding, ulceration, perforation.</paragraph>
                        <paragraph>Skin rash has been reported rarely.</paragraph>
                     </text>
                     <effectiveTime value="20230315"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_24a69611-911a-4af3-8186-9ef3f06ae404">
               <id root="24a69611-911a-4af3-8186-9ef3f06ae404"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20180827"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Triamterene and amiloride: Concomitant use is contraindicated
  
     <linkHtml href="#LINK_ad7de793-ce8c-4052-8e03-13d095b411a7">(7.1)</linkHtml>
                           </item>
                           <item>Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia
  
     <linkHtml href="#LINK_39b83713-960b-41cb-a0a0-a046349282b0">(7.2)</linkHtml>
                           </item>
                           <item>Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia
  
     <linkHtml href="#LINK_828930e3-3099-4227-95f2-f80f52e53707">(7.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ad7de793-ce8c-4052-8e03-13d095b411a7">
                     <id root="ad7de793-ce8c-4052-8e03-13d095b411a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Triamterene or amiloride</title>
                     <text>
                        <paragraph>Use with triamterene or amiloride can produce severe hyperkalemia. Concomitant use is contraindicated
 
  <content styleCode="italics">[see Contraindications
  
   (4)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180827"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_39b83713-960b-41cb-a0a0-a046349282b0">
                     <id root="39b83713-960b-41cb-a0a0-a046349282b0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Renin-angiotensin-aldosterone Inhibitors</title>
                     <text>
                        <paragraph>Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients on concomitant RAAS inhibitors.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_828930e3-3099-4227-95f2-f80f52e53707">
                     <id root="828930e3-3099-4227-95f2-f80f52e53707"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</title>
                     <text>
                        <paragraph>NSAIDS may produce potassium retention by reducing renal synthesis of prostaglandin E and imparing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2782b6bc-46c6-4f0a-852f-570e08bda292">
               <id root="2782b6bc-46c6-4f0a-852f-570e08bda292"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20230315"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Cirrhosis: Initiate therapy at the low end of the dosing range
  
     (8.6)</item>
                           <item>Renal Impairment: Initiate therapy at the low end of the dosing range
  
     <linkHtml href="#LINK_5b93c35c-108d-4d13-afab-c9653aee960c">(8.7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_483ca32f-15ed-4912-85c7-665152016fc4">
                     <id root="483ca32f-15ed-4912-85c7-665152016fc4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm.</paragraph>
                        <paragraph>The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230315"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7797fb3d-1709-4783-91a4-92379353d911">
                     <id root="7797fb3d-1709-4783-91a4-92379353d911"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_78f99527-fc7b-48b4-bc68-49dda448f90f">
                     <id root="78f99527-fc7b-48b4-bc68-49dda448f90f"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in the pediatric population have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_51788629-13d4-414a-ae88-6c826274d81e">
                     <id root="51788629-13d4-414a-ae88-6c826274d81e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f4d397f0-5304-49fe-9fc9-f89ce05a6d96">
                     <id root="f4d397f0-5304-49fe-9fc9-f89ce05a6d96"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Cirrhotics</title>
                     <text>
                        <paragraph>Based on publish literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load. Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently
 
  <content styleCode="italics">[</content>see
 
  <content styleCode="italics">Clinical Pharmacology
  
   (12.3)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230315"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5b93c35c-108d-4d13-afab-c9653aee960c">
                     <id root="5b93c35c-108d-4d13-afab-c9653aee960c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on RAAS inhibitors or NSAIDs, should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#LINK_39b83713-960b-41cb-a0a0-a046349282b0">7.2</linkHtml>,
  
   <linkHtml href="#LINK_828930e3-3099-4227-95f2-f80f52e53707">7.3</linkHtml>)]
 
  </content>. The serum potassium level should be monitored frequently. Renal function should be assessed periodically.

 </paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_70fbf856-3118-496c-9d0d-a9f2e27eb3bd">
               <id root="70fbf856-3118-496c-9d0d-a9f2e27eb3bd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text/>
               <effectiveTime value="20180827"/>
               <component>
                  <section ID="LINK_f8db4caf-d4f7-4483-90f8-b3fa0b00fa14">
                     <id root="f8db4caf-d4f7-4483-90f8-b3fa0b00fa14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Symptoms</title>
                     <text>
                        <paragraph>The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, potentially fatal hyperkalemia can result
 
  <content styleCode="italics">[see Contraindications and Warnings]</content>.

 </paragraph>
                        <paragraph>It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).</paragraph>
                     </text>
                     <effectiveTime value="20180827"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_63f5c9c2-4971-4585-8a08-9b3777e4f073">
                     <id root="63f5c9c2-4971-4585-8a08-9b3777e4f073"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Treatment</title>
                     <text>
                        <paragraph>Treatment measures for hyperkalemia include the following:</paragraph>
                        <paragraph>1. Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties.</paragraph>
                        <paragraph>2. Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL. 
  <br/>  3. Correction of acidosis, if present, with intravenous sodium bicarbonate. 
  <br/>  4. Use of exchange resins, hemodialysis or peritoneal dialysis.
 </paragraph>
                        <paragraph>In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.</paragraph>
                        <paragraph>The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4ba0aa5a-b606-44b2-a58f-747423c08149">
               <id root="4ba0aa5a-b606-44b2-a58f-747423c08149"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Potassium Chloride Extended-Release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet.</paragraph>
                  <paragraph>Potassium Chloride Extended-Release Tablets, USP are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Inactive Ingredients:</content>colloidal silicon dioxide, hydroxypropyl cellulose and hydrogenated vegetable oil. The film coating contains lecithin, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

 </paragraph>
                  <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
               </text>
               <effectiveTime value="20180527"/>
            </section>
         </component>
         <component>
            <section ID="LINK_80b82a8c-8e12-40b9-95c2-73c17798dc76">
               <id root="80b82a8c-8e12-40b9-95c2-73c17798dc76"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20180510"/>
               <component>
                  <section ID="LINK_1babcee1-0233-499c-b9ae-6693ec7607e9">
                     <id root="1babcee1-0233-499c-b9ae-6693ec7607e9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function.</paragraph>
                        <paragraph>The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.</paragraph>
                        <paragraph>Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e0f5ae8b-3485-4420-894d-d48b9239282b">
                     <id root="e0f5ae8b-3485-4420-894d-d48b9239282b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The potassium chloride in potassium chloride extended-release tablets is completely absorbed before it leaves the small intestine. The wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. When the bioavailability of the potassium ion from the potassium chloride extended-release tablets is compared to that of a true solution the extent of absorption is similar.</paragraph>
                        <paragraph>The extended-release properties of potassium chloride extended-release tablets are demonstrated by the finding that a significant increase in time is required for renal excretion of the first 50% of the potassium chloride extended-release tablets dose as compared to the solution.</paragraph>
                        <paragraph>Increased urinary potassium excretion is first observed 1 hour after administration of potassium chloride extended-release tablets, reaches a peak at approximately 4 hours, and extends up to 8 hours. Mean daily steady-state plasma levels of potassium following daily administration of potassium chloride extended-release tablets cannot be distinguished from those following administration of potassium chloride solution or from control plasma levels of potassium ion.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                     <component>
                        <section ID="LINK_dd0e3a3c-2bde-4ce0-9a87-9863fed2f1fb">
                           <id root="dd0e3a3c-2bde-4ce0-9a87-9863fed2f1fb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cirrhotics</content>
                              </paragraph>
                              <paragraph>Based on publish literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load.</paragraph>
                           </text>
                           <effectiveTime value="20180510"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_df76b2bb-d8c3-4eb8-9bed-140d89a0a385">
               <id root="df76b2bb-d8c3-4eb8-9bed-140d89a0a385"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20180510"/>
               <component>
                  <section ID="LINK_2d72b7b5-d128-4268-99aa-59412a35f723">
                     <id root="2d72b7b5-d128-4268-99aa-59412a35f723"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.</paragraph>
                     </text>
                     <effectiveTime value="20180510"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c5af2194-6956-4561-8439-463d89c1cf8c">
               <id root="22a73f35-3147-4478-a8fa-6e92d5e0403d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Potassium Chloride Extended-Release Tablets, USP contain 600 mg or 750 mg of Potassium Chloride, USP (equivalent to 8 mEq and 10 mEq respectively), and are provided as extended release tablets.</paragraph>
                  <table>
                     <caption> Table 1: How Supplied</caption>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Dose</content>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Shape</content>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Color</content>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Debossment</content>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Blistercards of 30 tablets</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="bold">Blistercards of 15 tablets</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">
                                 <content styleCode="bold">Blistercards of 14 tablets</content>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 600 mg (8 mEq)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Round</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> White to off-white</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> “YH” and “106” on one side, and “8” on the other side</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">n/a</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">n/a</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">n/a</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 750 mg (10 mEq)</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Round</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> White to off-white</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> “YH” and “105” on one side, and “10” on the other side</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0615-8570-39</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0615-8570-05</td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0615-8570-14</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature.] Protect from light and moisture.
</paragraph>
                  <paragraph>Dispense in a tight container as defined in the USP with a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20250227"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7264b5a2-afc5-4118-99ec-5e93128b316a">
               <id root="7264b5a2-afc5-4118-99ec-5e93128b316a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disk">
                     <item>Inform patients to take each dose with meals and with a full glass of water or other liquid, and to not crush, chew, or suck the tablets. Inform patients that the wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool.</item>
                     <item>Advise patients seek medical attention if tarry stools or other evidence of gastrointestinal bleeding is noticed.</item>
                  </list>
               </text>
               <effectiveTime value="20240315"/>
               <component>
                  <section ID="LINK_f7d0d683-5ddf-4861-820a-e6efefc556e3">
                     <id root="f7d0d683-5ddf-4861-820a-e6efefc556e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>Manufactured by: 
  <br/>  Yichang Humanwell Oral Solid Dosage Plant 
  <br/>  Yichang, Hubei, China 443001
 </paragraph>
                        <paragraph>Distributed by: 
  <br/>  Epic Pharma, LLC 
  <br/>  Laurelton, NY 11413
 </paragraph>
                        <paragraph>Revised 01/2024 
  <br/>  ZLN008
 </paragraph>
                     </text>
                     <effectiveTime value="20240315"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_244e5b6e-c0c0-421b-8a2e-bc8f73286bda">
               <id root="6e8d2824-9ec8-411d-9d72-bbdcb2c04a69"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20250227"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>PRINCIPAL DISPLAY PANEL</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="potassium-chloride-er-tabs-8570-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>